RATIONALE: Depletion of brain serotonin (5-HT) results in impulsive behaviour as measured by increased premature responding in the five-choice serial reaction time (5-CSRT) test. Acute selective blockade of 5-HT2C receptors also increases this form of impulsive action, whereas 5-HT2C receptor stimulation reduces premature responding. OBJECTIVES: These experiments determined the impact of genetic disruption of 5-HT2C receptor function on impulsive responding in the 5-CSRT test. METHODS: Food-restricted 5-HT2C receptor null mutant and wild-type (WT) mice were trained on the 5-CSRT test in which subjects detect and correctly respond to brief light stimuli for food reinforcement. Impulsivity is measured as premature responses that occur prior to stimulus presentation. RESULTS: Both lines of mice quickly learned this task, but there were no genotype differences in premature responding or any other aspect of performance. A series of drug challenges were then given. The 5-HT2C receptor agonist Ro60-0175 (0.6 mg/kg) reduced premature responding in WT mice but not mutant mice. The 5-HT2C receptor antagonist SB242084 increased premature responding in WT mice only. Cocaine increased premature responding at 7.5 mg/kg but not at a higher dose that disrupted overall responding; these effects were observed in both lines of mice. Amphetamine (0.25 and 0.5 mg/kg) did not affect premature responding, but disrupted other aspects of performance in both genotypes. CONCLUSIONS: Genetic deletion of 5-HT2C receptor function does not induce an impulsive state or exacerbate that state induced by psychomotor stimulants but does prevent the acute effects of 5-HT2C receptor stimulation or blockade on impulsive action.
RATIONALE: Depletion of brain serotonin (5-HT) results in impulsive behaviour as measured by increased premature responding in the five-choice serial reaction time (5-CSRT) test. Acute selective blockade of 5-HT2C receptors also increases this form of impulsive action, whereas 5-HT2C receptor stimulation reduces premature responding. OBJECTIVES: These experiments determined the impact of genetic disruption of 5-HT2C receptor function on impulsive responding in the 5-CSRT test. METHODS: Food-restricted 5-HT2C receptor null mutant and wild-type (WT) mice were trained on the 5-CSRT test in which subjects detect and correctly respond to brief light stimuli for food reinforcement. Impulsivity is measured as premature responses that occur prior to stimulus presentation. RESULTS: Both lines of mice quickly learned this task, but there were no genotype differences in premature responding or any other aspect of performance. A series of drug challenges were then given. The 5-HT2C receptor agonist Ro60-0175 (0.6 mg/kg) reduced premature responding in WT mice but not mutant mice. The 5-HT2C receptor antagonist SB242084 increased premature responding in WT mice only. Cocaine increased premature responding at 7.5 mg/kg but not at a higher dose that disrupted overall responding; these effects were observed in both lines of mice. Amphetamine (0.25 and 0.5 mg/kg) did not affect premature responding, but disrupted other aspects of performance in both genotypes. CONCLUSIONS: Genetic deletion of 5-HT2C receptor function does not induce an impulsive state or exacerbate that state induced by psychomotor stimulants but does prevent the acute effects of 5-HT2C receptor stimulation or blockade on impulsive action.
Authors: J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft Journal: J Pharmacol Exp Ther Date: 1998-08 Impact factor: 4.030
Authors: S M Bromidge; M Duckworth; I T Forbes; P Ham; F D King; K M Thewlis; F E Blaney; C B Naylor; T P Blackburn; G A Kennett; M D Wood; S E Clarke Journal: J Med Chem Date: 1997-10-24 Impact factor: 7.446
Authors: Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher Journal: Neuropsychopharmacology Date: 2011-12-21 Impact factor: 7.853
Authors: Beatriz A Rocha; Evan H Goulding; Laura E O'Dell; Andy N Mead; Nicole G Coufal; Loren H Parsons; Laurence H Tecott Journal: J Neurosci Date: 2002-11-15 Impact factor: 6.167
Authors: Marcel M van Gaalen; Reinhild J Brueggeman; Patricia F C Bronius; Anton N M Schoffelmeer; Louk J M J Vanderschuren Journal: Psychopharmacology (Berl) Date: 2006-04-25 Impact factor: 4.530
Authors: Rachel A Hill; Simon S Murray; Paul G Halley; Michele D Binder; Sally J Martin; Maarten van den Buuse Journal: Hippocampus Date: 2011-04 Impact factor: 3.899
Authors: Clinton E Canal; Uade B Olaghere da Silva; Paul J Gresch; Erin E Watt; Elaine Sanders-Bush; David C Airey Journal: Psychopharmacology (Berl) Date: 2010-02-19 Impact factor: 4.530
Authors: Markus Wöhr; Henrike Rippberger; Rainer K W Schwarting; Marcel M van Gaalen Journal: Psychopharmacology (Berl) Date: 2014-11-25 Impact factor: 4.530
Authors: Adam C Mar; Alexa E Horner; Simon R O Nilsson; Johan Alsiö; Brianne A Kent; Chi Hun Kim; Andrew Holmes; Lisa M Saksida; Timothy J Bussey Journal: Nat Protoc Date: 2013-09-19 Impact factor: 13.491
Authors: Amanda J Quisenberry; Celia R Eddy; David L Patterson; Christopher T Franck; Warren K Bickel Journal: PLoS One Date: 2015-08-17 Impact factor: 3.240